logo Recombinant Technologies
  • HOME
  • TECHNOLOGY
    • What Is AmyTrap
    • AmyTrap in Action
    • Current Pipeline
  • ABOUT US
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Partnerships
    • Funding
  • NEWS
    • Cure for Alzheimer's Disease
    • Better Living for People
  • CONTACT

Investors

  • Home
  •  
  • About Us

Connecticut Innovations Inc. (CII)

CII has awarded a bridge grant that is supporting the current efforts to improve the value of the small molecule therapeutic. CII has shown interest to continue to support future commercialization of this Alzheimer's drug.

  • What is AmyTrap

    To Know details

  • AmyTrap in Action

    To Know details

  • Current Pipeline

    To Know details

We are Here

RTL's current focus is on developing small molecules to treat Alzheimer's disease.

    Recombinant Technologies, LLC

    1090, Meriden Waterbury Road, Suite1

    06410, USA

    Tel: + (203) 271-3125, Fax: + (203) 271-3126

    E-mail: contact@recombtech.com


Releted Publications

  • Sundaram RK, Kasinathan C, Stein S, Sundaram P.Detoxification depots for beta amyloid Readmore
  • Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South India. Readmore
  • Novel detox gel depot sequesters β- Amyloid Peptides in a mouse model of Alzheimer's disease. Readmore
  • Patents on potential drugs to treat Alzheimer's Disease: Special emphasis on small peptides. Readmore

Related Links

  • http://www.alzforum.org/ Click Here

  • Releated Link 2 Click here

  • Related Link 3 Click Here.

  • Related Link 4 Click Here

  • Related Link 5 Click Here

Copyright 2014-2016 Recombinant Technologies | All Rights Reserved | Powered by i-Grandee Software Technologies Pvt.Ltd
Top